Trasis Maps April 2026 Radiopharma Conference Circuit for Nuclear Medicine Professionals

Trasis published its April 2026 conference schedule last week, mapping a run from Rio de Janeiro to Bergen to Germany that places its synthesis hardware in front of the practitioners and regulators most likely to drive the next round of radiopharma supply contracts. The five-country stretch across Brazil, Norway, the UK, Germany, and the United States compresses some of the field's most consequential annual gatherings into fewer than two weeks.

The event drawing the sharpest industry attention is the 13th International Symposium on Targeted Alpha Therapy, TAT 13, running April 14-16 at the Windsor Barra Convention Center in Rio de Janeiro. Organized by the Brazilian Society of Nuclear Medicine and Molecular Imaging alongside the European Commission's Joint Research Centre, TAT 13 is the most concentrated annual gathering for actinium-225 supply-chain discussions, alpha-emitter clinical pipeline updates, and regulatory strategy. Trasis operates from booth 5, showing its miniAllinOne compact synthesis module, QC1 quality-control platform, and SteriNow dispensing system, the instrument stack that would process Ac-225 at scale once the supply bottleneck constraining several Phase III programs is resolved. The supply-chain sessions here are where manufacturers, isotope producers, and clinical teams negotiate the production agreements that precede regulatory submissions, making TAT 13 the single highest-signal event of the month for anyone tracking alpha-therapy market moves.

Two days later, ESRR 2026, the biennial congress of the European Society of Radiopharmacy and Radiochemistry, opens April 16-19 at the Grieghallen in Bergen, Norway. Structurally linked to the European Association of Nuclear Medicine, ESRR reliably surfaces new EU regulatory guidance on radiopharmacy quality standards, GMP compliance updates, and early-phase development pathways. Trasis takes booth 7 with its Streamline platform for early-stage radiopharmaceutical development and its full AllinOne automated synthesis lineup, precisely the equipment that translates regulatory requirements into hardware specifications for cyclotron and generator facilities.

The DGN, the annual Jahrestagung of the Deutsche Gesellschaft für Nuklearmedizin, follows April 22-25 and is Germany's largest nuclear medicine gathering. Trasis occupies booth C16 to demonstrate the Unidose hospital dispensing system, LME shielded enclosures, and EasyOne cold-kit labelling and dispensing equipment. The DGN's scale and clinical-operations focus make it a consistent venue for hospital procurement discussions, which often surface publicly before formal supply tender announcements.

UK and US stops round out the April circuit, giving Trasis a near-continuous three-continent presence during a period when pre-summer contracting conversations accelerate across the sector. For anyone building a conference watchlist, the overlap between TAT 13 and ESRR on April 16 is the critical window: alpha-therapy supply news from Rio can land the same day EU regulatory signals emerge in Bergen. Technical posters and vendor whitepapers from both events typically circulate within weeks, and ESRR proceedings in particular carry early indicators of shifts in member-state GMP enforcement priorities. Trasis's itinerary effectively traces the circuit where that intelligence is made.